Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coegin PharmaNGM:COEGIN -2.00%27 EV-to-EBIT is -3.99 as of Aug. 22, 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 373 Biotechnology companies, Coegin Pharma ranks worse than 268096.25% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Coegin Pharma's Enterprise Value for the quarter that ended in Mar. 2026 was kr101.95 Mil.
Coegin Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-19.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coegin Pharma EV-to-EBIT Related Terms
Coegin Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:COEGIN vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Coegin Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coegin Pharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coegin Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Coegin Pharma's EV-to-EBIT falls into.
Coegin Pharma's current Enterprise Value is kr78.15 Mil.
Coegin Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-19.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coegin Pharma (NGM:COEGIN) has a EV-to-EBIT of -3.99 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Coegin Pharma and its competitors. According to the industry distribution chart, Coegin Pharma ranks #999999 out of 373 companies in the Biotechnology industry.
Is Coegin Pharma's EV-to-EBIT too high?
Coegin Pharma's current EV-to-EBIT is -3.99. Based on the distribution chart, Coegin Pharma ranks #999999 out of 373 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coegin Pharma has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coegin Pharma ranks #999999 out of 373 companies for EV-to-EBIT. This places Coegin Pharma in the lower half of its industry. The industry median EV-to-EBIT is 15.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.29, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Coegin Pharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coegin Pharma's current EV-to-EBIT is -3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current EV-to-EBIT of -3.99. The current EV-to-EBIT is -3.99. Coegin Pharma's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current EV-to-EBIT is -3.99 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
27GF Score
Get the complete analysis for NGM:COEGIN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
